Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid β-protein

Wesley Farris, Malcolm A. Leissring, Matthew L. Hemming, Alice Y. Chang, Dennis J. Selkoe

Research output: Contribution to journalArticlepeer-review

70 Scopus citations


Deletion of insulin-degrading enzyme (IDE) in mice causes accumulation of cerebral amyloid β-protein (Aβ), hyperinsulinemia, and glucose intolerance. Together with genetic linkage and allelic association of IDE to Alzheimer's disease (AD) and type 2 diabetes mellitus (DM2), these findings suggest that IDE hypofunction could mediate human disease. To date, no coding mutations have been found in the canonical isoform of IDE, suggesting that pathological mutations could exist in undiscovered exons or regulatory regions, including untranslated regions (UTRs). However, neither isoforms arising from alternative splicing nor the UTRs have been described. Here, we systematically characterize human IDE mRNAs, identify a novel splice form, and compare its subcellular distribution, kinetic properties, and ability to degrade Aβ to the known isoform. Six distinct human IDE transcripts were identified, with most of the variance attributable to alternative polyadenylation sites. In the novel spliceoform, an exon we designate "15b" replaces the canonical exon "15a", and the resultant variant is widely expressed. Subcellular fractionation, immunofluorescent confocal microscopy, and immunogold-electron microscopy reveal that the 15b-IDE protein occurs in both cytosol and mitochondria. Organelle targeting of both isoforms is determined by which of two translation start sites is used, and only those isoforms utilizing the second site regulate levels of secreted Aβ. 15b-IDE can exist as a heterodimer with the 15a isoform or as a homodimer. The apparent Km values of recombinant 15b-IDE for both insulin and Aβ are significantly higher and the kcat and catalytic efficiency markedly lower than those of 15a-IDE. In accord, cells coexpressing β-amyloid precursor protein (APP) and 15b-IDE accumulated significantly more Aβ in their media than those expressing APP and 15a-IDE. Our results identify a novel, catalytically inefficient form of IDE expressed in brain and non-neural tissues and recommend novel regions of the IDE gene in which to search for mutations predisposing patients to AD and DM2.

Original languageEnglish (US)
Pages (from-to)6513-6525
Number of pages13
Issue number17
StatePublished - May 3 2005

ASJC Scopus subject areas

  • Biochemistry


Dive into the research topics of 'Alternative splicing of human insulin-degrading enzyme yields a novel isoform with a decreased ability to degrade insulin and amyloid β-protein'. Together they form a unique fingerprint.

Cite this